Contemporary approach to treating heart failure.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Heart failure (HF) treatment has evolved significantly, shifting from solely managing congestion to utilizing neurohormonal modulation.
• Randomized clinical trials (RCTs) demonstrate that neurohormonal blocking agents reduce morbidity, mortality, and improve quality of life in HF patients.
• Historically, HF trials have stratified patients by ejection fraction (EF), with most therapeutic benefits observed in heart failure with reduced ejection fraction (HFrEF).

Purpose of the Study:

• To review current medical management strategies for heart failure (HF) across the spectrum of ejection fraction (EF).
• To highlight the underutilization of established HF therapies and its impact on patient outcomes.
• To provide clinicians with the rationale for specific agent use and a practical approach to patient management.

Main Methods:

• Review of randomized clinical trials (RCTs) in heart failure (HF).
• Analysis of current guideline recommendations for HF management.
• Incorporation of authors' clinical experience in managing HF patients.

Main Results:

• Effective agents primarily benefit patients with reduced ejection fraction (HFrEF), with fewer options for heart failure with preserved ejection fraction (HFpEF).
• Underutilization of available HF therapies significantly limits their overall impact on patient outcomes.
• Neurohormonal modulating drugs have shown substantial benefits in reducing morbidity and mortality.

Conclusions:

• Current HF management strategies, particularly those targeting neurohormonal pathways, offer significant benefits, especially in HFrEF.
• Addressing the underutilization of evidence-based therapies is crucial for improving HF patient outcomes.
• A practical, evidence-based approach to HF management across the EF spectrum is essential for clinicians.